Chu, Q.; Sripada, K.; Vaselenak, S.; Jovanoski, N.; Arnold, M.
Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada. Curr. Oncol. 2024, 31, 3301-3310.
https://doi.org/10.3390/curroncol31060251
AMA Style
Chu Q, Sripada K, Vaselenak S, Jovanoski N, Arnold M.
Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada. Current Oncology. 2024; 31(6):3301-3310.
https://doi.org/10.3390/curroncol31060251
Chicago/Turabian Style
Chu, Quincy, Kaushik Sripada, Sarah Vaselenak, Nick Jovanoski, and Melina Arnold.
2024. "Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada" Current Oncology 31, no. 6: 3301-3310.
https://doi.org/10.3390/curroncol31060251
APA Style
Chu, Q., Sripada, K., Vaselenak, S., Jovanoski, N., & Arnold, M.
(2024). Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada. Current Oncology, 31(6), 3301-3310.
https://doi.org/10.3390/curroncol31060251